JPRN-UMIN000003330已完成2 期
Phase II study of nedaplatin plus irinotecan for stage III/IV squamous cell lung cancer (TORG0910) - Phase II study of nedaplatin plus irinotecan for squamous cell lung cancer
Thoracic Oncology Research Group (TORG)0 个研究点目标入组 50 人开始时间: 2010年3月15日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Massive pleural effusion 2)Massive pericardial effusion 3)double cancer 4)severe complications; myocardial infarction, unstable angina, heart failure, uncontrolled hypertension, ued uncontrolled diabetis mellitus, uncontrolled infection, uncontrolled mental disease, SVC syndrome 5)irinotecan contraindication; watery diarrhea, ileus, digestive organs bleeding, jaundice, bone marrow suppression 6)nedaplatin contraindication; renal failure 7)lung fibrosis 8)pregnancy 9)other inappropriate cases
研究者
相似试验
已完成
2 期
A phase II study of nedaplatin plus irinotecan for stage III/IV and EGFR mutation negative non-small cell lung cancer with high-risk factorsJPRN-UMIN000003622Kanagawa Cancer Center35
招募中
2 期
Phase II Study of cisplatin plus irinotecan for large cell neuroendocrine carcinomaarge cell neuroendocrine carcinomaJPRN-UMIN000004796ational Cancer Research Center Hospital East44
已完成
不适用
Phase II trial of irinotecan plus cisplatin for pretreated patients with Ewing sarcoma and PNETpretreated Ewing sarcoma or PNETJPRN-UMIN000001529ational cancer center hospital32
已完成
2 期
phase II study of irinotecan plus cisplatin followed by amrubicin in patients with extensive disease small-cell lung cancer.extensive disease small-cell lung cancerJPRN-C000000113West Japan Oncology Group45
已完成
1 期
Phase 1/2 study of the combination of nedaplatin and ifosfamide in patients with advanced or recurrent cervical cancerAdvanced or recurrent cervical cancerJPRN-UMIN000000464Graduate School of Medicine, Chiba University25